statementSaid on 2026-11-06

On October 17, 2026, the National Pharmaceutical Pricing Authority (NPPA) capped the trade margin on 137 non-scheduled anti-cancer medicines, including patented ones, at 30% of the maximum retail price (MRP).

A statement by post author, said on 2026-11-06. Statements are as reported by the cited publishers — not verified by DecisionGateway.

On October 17, 2026, the National Pharmaceutical Pricing Authority (NPPA) capped the trade margin on 137 non-scheduled anti-cancer medicines, including patented ones, at 30% of the maximum retail price (MRP)
pib_backgroundersPublished 2026-11-06 Read source

Discussion

0/2000

Related claims